A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO) Meeting Abstract
| Authors: | Turner, N. C.; Balmana, J.; Fasching, P. A.; Hurvitz, S. A.; Telli, M. L.; Visco, F.; Wardley, A. M.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Robson, M. E. |
| Abstract Title: | A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904663 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.tps1108 |
| Notes: | Meeting Abstract: TPS1108 -- Source: Wos |
